Inovio Misses On Normalized Loss, But VOCERYQ Approval And $80.5 Million Raise Reset The Story Around Launch Execution

Inovio Pharmaceuticals reported a third-quarter loss of $0.23 per share on Earnings Whispers' normalized basis, a penny-sized but 15.0% miss against the -$0.20 consensus. The loss still improved 47.7% year over year. Revenue was just $0.3 million, all from collaborative arrangements. The quarter itself barely matters, though. Two days before the period's reporting window closed out the old narrative, on October 30, the FDA granted accelerated approval to VOCERYQ (INO-3107) to reduce surgery frequency in adults with recurrent respiratory papillomatosis (RRP). It is the first FDA-approved DNA medicine. Inovio is now a commercial-stage company, and the investment question has shifted from whether regulators will say yes to whether the company can sell against an entrenched competitor before its cash runs out.

The headline numbers need some translation. On a GAAP basis, Inovio lost $49.2 million, or $0.50 per share, compared with $45.5 million, or $0.87, a year ago. The gap from the normalized figure is largely a $26.9 million non-cash loss on warrant liabilities. That charge rises as the share price rises, so the stock's rally mechanically inflated the reported loss. Underlying spending was disciplined:

• Total operating expenses fell to $19.8 million from $21.2 million.
• R&D dropped to $10.6 million from $13.3 million.
• SG&A rose to $9.2 million from $7.9 million as launch preparation began.

The per-share improvement is flattered by dilution, however. Weighted shares nearly doubled to 98.6 million from 52.2 million, and the balance sheet showed negative stockholders' equity of $33.9 million at quarter-end, driven by $70 million in warrant liabilities.

The call marked a clear break from prior quarters. The last three calls were dominated by FDA's preliminary skepticism over accelerated-approval eligibility. This one laid out a concrete commercial plan:

• **Field force:** 20 territories staffed through Syneos Health.
• **Account focus:** roughly 100 integrated delivery networks and academic accounts covering about 80% of patients.
• **Timing:** product available to ship about 60 days after approval, with full field deployment in the first quarter of 2027.
• **Supply:** inventory sufficient for at least all of 2027.
• **Market size:** management lifted its U.S. prevalence estimate to at least 25,000 adults, up from the roughly 14,000 published figure referenced earlier in the year.

The financing matters as much as the approval. The $80.5 million net offering, plus $10.9 million from warrant exercises, layered on $48.4 million in quarter-end cash, extends the runway to late fourth quarter 2027. That is the fourth consecutive quarterly extension, up from late first quarter 2027 just three months ago.

Bears still have legitimate ammunition, and the approval details supply much of it. FDA's efficacy analysis centered on a 26-patient subset with a 27% complete response rate in year one. That is a considerably narrower framing than the company's messaging of 50% to 100% surgery reduction. Continued approval depends on a confirmatory study of at least 50 patients, including pediatrics, with three or more years of follow-up, and protocol alignment is not targeted until mid-2027. Commercially, VOCERYQ enters a market where Papzimeos already has strong uptake; roughly 200 patients were cited last quarter. Payer coverage is expected to reach about 80% of lives only within nine months of approval. Meanwhile, cash burn is guided up to about $21 million in the fourth quarter from roughly $18 million, and the runway projection excludes any product revenue. That cuts both ways: it leaves upside if the launch works, and it raises the odds of further dilution if it stalls. Optional upside includes a European conditional marketing filing before year-end, ex-U.S. partnering, and potential DPROT platform deals in hemophilia A, Fabry disease and hypophosphatasia.

The stock's path through the approval captures the setup. Shares hit their inter-earnings low of $0.60 on October 30, the approval date. They then spiked to a high of $2.17 just three days later, on November 2. At $1.51 ahead of the report, the stock had given back about 30% of that peak, a retreat consistent with the dilutive offering. Even so, shares are up 86.4% since the open following the August report and sit 19.3% above their 200-day moving average of $1.27. Investor sentiment improved meaningfully, rising from 0.46 to 0.66, which reflects genuine relief over the regulatory outcome. The Earnings Whispers trend readings are mixed: AVWAP is positive, while sequential growth remains negative, a reminder that operating results have yet to show any commercial traction.

The bottom line is that the 15% miss on the normalized loss is noise next to the approval that turned Inovio into a commercial company and the financing that funds it through 2027. The quarter removed the binary regulatory risk but replaced it with execution risk. That risk spans payer access, a confirmatory trial and a well-established rival, against a narrower FDA efficacy framing than management's marketing pitch. The post-approval pullback suggests investors are already weighing those questions. Early 2027 prescription and coverage data will matter far more than anything in this report.

Read our earnings preview for Inovio Pharmaceuticals, Inc.: https://www.earningswhispers.com/article/INO/22801

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.